Last reviewed · How we verify
INDISULAM
At a glance
| Generic name | INDISULAM |
|---|---|
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
- Nausea
- Diarrhea
- Hypokalemia
- Fatigue
- Hypomagnesemia
- Hyperbilirubinemia
- Edema
- Constipation
- Hyperglycemia
- Skin and Subcutaneous tissue disorders
- Hypocalcemia
- Anorexia
Key clinical trials
- Dose-Finding Study of E7070 in Combination With Irinotecan (PHASE1)
- E7070, Idarubicin and Cytarabine in Relapsed AML and High-Risk Myelodysplastic Syndromes (PHASE2)
- An Open-label, Randomized, Phase II Study of the Efficacy and Safety of Indisulam (E7070) in Combination With Capecitabine (PHASE2)
- Study of E7070 Combined With Capecitabine to Determine Efficacy and Recommended Dose of Combination in Patients With Metastatic Colorectal Cancer (PHASE2)
- A Study of E7070 in Patients With Gastric Cancer (PHASE1, PHASE2)
- E7070 in Treating Patients With Stage IV Melanoma (PHASE2)
- E7070 in Treating Patients With Solid Tumors (PHASE1)
- E7070 in Treating Patients With Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- INDISULAM CI brief — competitive landscape report
- INDISULAM updates RSS · CI watch RSS